Skip to content

Safety of Early Discharge Following Low Risk Myocardial Infarction

Safety of a Early Discharge Strategy in Patients With Low-risk ST-segment Elevation Myocardial Infarction Treated With Primary Coronary Intervention: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01868256
Acronym
EDAMI
Enrollment
1558
Registered
2013-06-04
Start date
2012-01-31
Completion date
2014-02-28
Last updated
2013-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

myocardial infarction, primary percutaneous intervention, prognosis, early discharge

Brief summary

* Objectives: The primary objective of this study is to evaluate the safety of an early discharge strategy in patients with low risk ST-elevation myocardial infarction (STEMI), treated with primary percutaneous coronary intervention (PPCI), compared to a conventional strategy. * Methodology: Unicentric, randomized, controlled, non-inferiority and open label clinical trial. The investigators will compare an early discharge strategy (≤72 hours) with a conventional strategy (discharge according to treating physician's criterion). Inclusion criteria will be: low risk (Zwolle risk score ≤3) STEMI treated with PPCI within 24 hours from symptoms onset. Exclusion criteria will be: arrhythmias (ventricular tachycardia or fibrillation, asystole, pulseless electrical activity, advanced atrio-ventricular block), mechanical complications (cardiac tamponade, free-wall or septal rupture, acute mitral regurgitation, pericarditis), severe or moderate bleeding (according to the GUSTO criteria), complications related to vascular access of the procedure, acute kidney failure, infection, heart failure. Sample size will be 1558 subjects (n=779 per group). The investigators will study demographic, clinical, biochemical, echocardiographic and angiographic variables. The primary endpoint will be a composite of death, reinfarction, new angina, heart failure, ventricular arrhythmias, stroke and severe bleeding. The secondary endpoint will include each of the items of the primary endpoint and quality of life and functional capacity questionnaire SF-36. Finally, the investigators will analyze the degree of compliance with the European Society of Cardiology guidelines on STEMI and the rate of hospitalization-related complications. Follow up will be at 30 days.

Interventions

OTHERearly discharge (<72 h)

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* low risk (Zwolle risk score ≤3) STEMI treated with PPCI within 24 hours from symptoms onset * Informed consent

Exclusion criteria

* arrhythmias (ventricular tachycardia or fibrillation, asystole, pulseless electrical activity, advanced atrio-ventricular block) * mechanical complications (cardiac tamponade, free-wall or septal rupture, acute mitral regurgitation, pericarditis) * severe or moderate bleeding (according to the GUSTO criteria) * complications related to vascular access of the procedure * acute kidney failure * infection * heart failure

Design outcomes

Primary

MeasureTime frameDescription
All cause mortality, new acute myocardial infarction, new unstable angina, heart failure, ventricular arrhythmias, stroke and severe bleeding.1 monthComposite primary end-point

Secondary

MeasureTime frameDescription
All cause mortality1 month
Myocardial infarction1 month
Unstable angina1 month
Heart failure1 month
Stroke1 month
Severe bleeding1 monthAccording to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification
Ventricular arrhythmias1 month

Other

MeasureTime frame
Difference in quality of life and functional capacity questionnaire SF-36.1 month
Compliance of treatment1 month

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026